Back

Direct oral anticoagulant rivaroxaban in very old and frail patients: A one-year prospective follow-up of a large-scale cohort (SAFIR-AC)

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Atrial fibrillation: from drugs to ablation Antiarrhythmic Drug Treatment ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Olivier Hanon

Hospital Broca of Paris, Paris (France)

3 More presentations in this session

Presentation thumbnail
Blood pressure and white matter lesions in patients with atrial fibrillation
Professor D. Conen (Hamilton, CA)
Abstract Slides Video
Presentation thumbnail
Impact of AF type on the outcome of atrial fibrillation ablation: insights from the CABANA trial
Assistant Professor K. Monahan (Rochester, US)
Abstract Slides Video
Presentation thumbnail
Are the results of the CASTLE-AF trial reproducible in the real life? Clinical outcomes after catheter ablation for atrial fibrillation with heart failure in a nationwide cohort study
Professor L. Fauchier (Tours, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial fibrillation: from drugs to ablation

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources